PE20210124A1 - FORMAS CRISTALINAS DE UN ESTIMULANTE DE LA GUANILIL CICLASA SOLUBLE (sGC) - Google Patents

FORMAS CRISTALINAS DE UN ESTIMULANTE DE LA GUANILIL CICLASA SOLUBLE (sGC)

Info

Publication number
PE20210124A1
PE20210124A1 PE2020001347A PE2020001347A PE20210124A1 PE 20210124 A1 PE20210124 A1 PE 20210124A1 PE 2020001347 A PE2020001347 A PE 2020001347A PE 2020001347 A PE2020001347 A PE 2020001347A PE 20210124 A1 PE20210124 A1 PE 20210124A1
Authority
PE
Peru
Prior art keywords
crystalline forms
crystalline
powder
ray diffraction
diffraction peaks
Prior art date
Application number
PE2020001347A
Other languages
English (en)
Spanish (es)
Inventor
Kwame W Nti-Addae
Leena Kumari Prasad
Thomas Storz
Original Assignee
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65818696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20210124(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cyclerion Therapeutics Inc filed Critical Cyclerion Therapeutics Inc
Publication of PE20210124A1 publication Critical patent/PE20210124A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2020001347A 2018-03-07 2019-03-07 FORMAS CRISTALINAS DE UN ESTIMULANTE DE LA GUANILIL CICLASA SOLUBLE (sGC) PE20210124A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862639846P 2018-03-07 2018-03-07
PCT/US2019/021080 WO2019173551A1 (en) 2018-03-07 2019-03-07 Crystalline forms of an sgc stimulator

Publications (1)

Publication Number Publication Date
PE20210124A1 true PE20210124A1 (es) 2021-01-19

Family

ID=65818696

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001347A PE20210124A1 (es) 2018-03-07 2019-03-07 FORMAS CRISTALINAS DE UN ESTIMULANTE DE LA GUANILIL CICLASA SOLUBLE (sGC)

Country Status (21)

Country Link
US (3) US11466015B2 (enExample)
EP (1) EP3762389B1 (enExample)
JP (1) JP7423539B2 (enExample)
KR (1) KR102782810B1 (enExample)
CN (1) CN111836812A (enExample)
AU (1) AU2019231724B2 (enExample)
BR (1) BR112020018212A2 (enExample)
CA (1) CA3092683A1 (enExample)
CL (5) CL2020002284A1 (enExample)
CO (1) CO2020012493A2 (enExample)
CR (1) CR20200458A (enExample)
EA (1) EA202092109A1 (enExample)
ES (1) ES2980256T3 (enExample)
IL (1) IL276853B2 (enExample)
MA (1) MA54638A (enExample)
MX (5) MX2020009183A (enExample)
PE (1) PE20210124A1 (enExample)
PH (1) PH12020551394A1 (enExample)
SG (1) SG11202008641WA (enExample)
TW (1) TWI823903B (enExample)
WO (1) WO2019173551A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111836812A (zh) 2018-03-07 2020-10-27 塞科里昂医疗股份有限公司 sGC刺激剂的晶型
US12220414B2 (en) * 2018-07-11 2025-02-11 Tisento Therapeutics Inc. Use of sGC stimulators for the treatment of mitochondrial disorders
US20230130739A1 (en) * 2020-03-26 2023-04-27 Cyclerion Therapeutics, Inc. DEUTERATED sGC STIMULATORS
CN118221651A (zh) * 2022-12-21 2024-06-21 广东东阳光药业股份有限公司 氟取代的吲唑化合物的晶型及其用途
AU2023412228A1 (en) * 2022-12-21 2025-07-03 Sunshine Lake Pharma Co., Ltd. Crystal form of fluorine-substituted indazole compound and use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
CZ302691B6 (cs) 1998-07-08 2011-09-07 Sanofi - Aventis Deutschland GmbH N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
CN101939053A (zh) 2007-09-06 2011-01-05 默沙东公司 可溶性的鸟苷酸环化酶活化剂
CA2711134A1 (en) 2008-01-24 2009-07-30 Merck Sharp & Dohme Corp. Angiotensin ii receptor antagonists
CA2743864A1 (en) 2008-11-25 2010-06-10 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CA2753434C (en) 2009-02-26 2014-07-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US9284301B2 (en) 2010-03-25 2016-03-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
UA107112C2 (uk) 2010-05-27 2014-11-25 Мерк Шарп Енд Доме Корп. Активатори розчинної гуанілатциклази
TWI532737B (zh) 2010-06-30 2016-05-11 艾諾屋製藥公司 可溶性鳥苷酸環化酶（ｓＧＣ）刺激物
WO2012058132A1 (en) 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
JP5878546B2 (ja) 2010-11-09 2016-03-08 アイアンウッド ファーマシューティカルズ インコーポレイテッド ｓＧＣ刺激剤
EP2927231B1 (en) 2012-11-30 2017-09-20 Astellas Pharma Inc. Imidazopyridine compounds
US9776997B2 (en) 2013-06-04 2017-10-03 Bayer Pharma Aktiengesellschaft 3-aryl-substituted imidazo[1,2-A]pyridines and their use
CN104327107A (zh) * 2013-10-17 2015-02-04 广东东阳光药业有限公司 一种氟喹诺酮类抗菌药物的制备方法
US9796733B2 (en) 2014-06-04 2017-10-24 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
US10844064B2 (en) 2014-09-17 2020-11-24 Cyclerion Therapeutics, Inc. sGC stimulators
EP3227286B1 (de) * 2014-12-02 2018-12-26 Bayer Pharma Aktiengesellschaft Substituierte pyrazolo[1,5-a]pyridine und imidazo[1,2-a]pyrazine und ihre verwendung
IL264955B (en) 2016-09-02 2022-06-01 Ironwood Pharmaceuticals Inc Fused bicyclic sgc stimulators
CN111836812A (zh) 2018-03-07 2020-10-27 塞科里昂医疗股份有限公司 sGC刺激剂的晶型

Also Published As

Publication number Publication date
EP3762389B1 (en) 2024-02-28
IL276853B1 (en) 2026-01-01
MA54638A (fr) 2021-11-10
CL2021003536A1 (es) 2022-08-19
KR102782810B1 (ko) 2025-03-14
WO2019173551A8 (en) 2020-06-11
CR20200458A (es) 2020-11-09
CO2020012493A2 (es) 2020-10-30
IL276853B2 (en) 2026-05-01
US20250115611A1 (en) 2025-04-10
AU2019231724A1 (en) 2020-10-08
TWI823903B (zh) 2023-12-01
CL2021000301A1 (es) 2021-06-18
TW201940487A (zh) 2019-10-16
EP3762389A1 (en) 2021-01-13
MX2020009183A (es) 2020-10-08
MX2023004857A (es) 2023-11-24
ES2980256T3 (es) 2024-09-30
CN111836812A (zh) 2020-10-27
US12122782B2 (en) 2024-10-22
IL276853A (en) 2020-10-29
PH12020551394A1 (en) 2021-11-22
CA3092683A1 (en) 2019-09-12
EA202092109A1 (ru) 2021-03-04
CL2020002284A1 (es) 2020-11-27
WO2019173551A1 (en) 2019-09-12
JP7423539B2 (ja) 2024-01-29
KR20200128708A (ko) 2020-11-16
MX2023004856A (es) 2023-11-24
US11466015B2 (en) 2022-10-11
MX2023004855A (es) 2023-11-24
CL2021003530A1 (es) 2022-08-19
US20230095799A1 (en) 2023-03-30
MX2023004858A (es) 2023-11-24
BR112020018212A2 (pt) 2020-12-29
JP2021515015A (ja) 2021-06-17
AU2019231724B2 (en) 2024-06-27
CL2021003531A1 (es) 2022-08-19
SG11202008641WA (en) 2020-10-29
US20210115050A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
AR113758A1 (es) Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo
CR20250252A (es) FORMAS EN ESTADO SÓLIDO (Divisional 2021-0665)
CR20190255A (es) PROCESO PARA LA PREPARACIÓN DE PIRAZOLO[1,5-a]PIRIMIDINAS Y SALES DE ESTAS
EA201990519A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА (S)-7-(1-АКРИЛОИЛПИПЕРИДИН-4-ИЛ)-2-(4-ФЕНОКСИФЕНИЛ)-4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-a]ПИРИМИДИН-3-КАРБОКСАМИДА, ЕЕ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЯ
WO2018045276A8 (en) Fused bicyclic sgc stimulators
CO2020012493A2 (es) Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc)
PE20201185A1 (es) Inhibidores de la oxacina monoacilglicerol lipasa (magl)
CL2017001617A1 (es) Formas sólidas de un inhibidor ask1 referencia cruzada a aplicaciones relacionadas
UY37854A (es) Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos
EA201790259A1 (ru) СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА
PE20171179A1 (es) Formas en estado solido de pirrolidinonas heteroaromaticas fusionadas
MX2010009414A (es) Derivados de imidazo-[1,2-b]-piridazina para el tratamiento de enfermedad mediada por cinasa de tirosina c-met.
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
TN2018000376A1 (en) Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine-3(2h)-ones and 2,5,6,7-tetrahydro-3h-pyrrolo[2,1-c][1,2,4]triazol-3-ones, and use thereof.
PE20171104A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
WO2016010869A3 (en) FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS
MX2014003194A (es) 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
MX2024007951A (es) Sales y formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para su preparacion.
ZA201805790B (en) Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and "azd9291 aniline" or a salt thereof
PE20210157A1 (es) Polimorfos y formas solidas de un compuesto de pirimidinilamino-pirazol y metodos de produccion
WO2015165933A3 (de) Imidazo[1,2-a]pyridine als stimulatoren der löslichen guanylatcyclase zur behandlung von kardiovaskulären erkrankungen
RU2019135690A (ru) Терапевтическое средство для лечения болезни телец леви, содержащее производное пиразолохинолина
AR116119A1 (es) Formas cristalinas de un inhibidor de fosfoinositida 3-quinasa (pi3k)
NZ739083B2 (en) Plinabulin compositions